JPWO2020201038A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020201038A5
JPWO2020201038A5 JP2021557778A JP2021557778A JPWO2020201038A5 JP WO2020201038 A5 JPWO2020201038 A5 JP WO2020201038A5 JP 2021557778 A JP2021557778 A JP 2021557778A JP 2021557778 A JP2021557778 A JP 2021557778A JP WO2020201038 A5 JPWO2020201038 A5 JP WO2020201038A5
Authority
JP
Japan
Prior art keywords
lipocalin mutein
lipocalin
medicament according
administered
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526367A (ja
JP2022526367A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/058637 external-priority patent/WO2020201038A1/en
Publication of JP2022526367A publication Critical patent/JP2022526367A/ja
Publication of JPWO2020201038A5 publication Critical patent/JPWO2020201038A5/ja
Publication of JP2022526367A5 publication Critical patent/JP2022526367A5/ja
Withdrawn legal-status Critical Current

Links

JP2021557778A 2019-03-29 2020-03-27 リポカリンムテインの吸入投与 Withdrawn JP2022526367A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962826767P 2019-03-29 2019-03-29
US62/826,767 2019-03-29
EP19166435 2019-04-01
EP19166435.8 2019-04-01
EP19175818 2019-05-22
EP19175818.4 2019-05-22
EP19177568.3 2019-05-31
EP19177568 2019-05-31
EP19211404 2019-11-26
EP19211404.9 2019-11-26
PCT/EP2020/058637 WO2020201038A1 (en) 2019-03-29 2020-03-27 Inhaled administration of lipocalin muteins

Publications (3)

Publication Number Publication Date
JP2022526367A JP2022526367A (ja) 2022-05-24
JPWO2020201038A5 true JPWO2020201038A5 (https=) 2023-04-03
JP2022526367A5 JP2022526367A5 (https=) 2023-04-03

Family

ID=70292935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557778A Withdrawn JP2022526367A (ja) 2019-03-29 2020-03-27 リポカリンムテインの吸入投与

Country Status (8)

Country Link
US (1) US20220168387A1 (https=)
EP (1) EP3946417A1 (https=)
JP (1) JP2022526367A (https=)
KR (1) KR20210146999A (https=)
CN (1) CN113939307A (https=)
AU (1) AU2020253034A1 (https=)
CA (1) CA3127973A1 (https=)
WO (1) WO2020201038A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
KR20230121785A (ko) * 2020-12-18 2023-08-21 아스트라제네카 에이비이 천식 치료용 리포칼린 뮤테인 건조 분말 제형

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
US8313924B2 (en) * 2006-08-01 2012-11-20 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
CN106986926A (zh) * 2008-01-30 2017-07-28 皮里斯股份公司 具有对人c‑met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
BR112012013662B1 (pt) * 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
RU2569745C2 (ru) * 2010-06-08 2015-11-27 Пиерис АГ Мутеины липокалина слезы, связывающие альфа il-4 r
NZ606584A (en) 2010-08-16 2014-10-31 Pieris Ag Binding proteins for hepcidin
US9260492B2 (en) * 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
EP2646552B1 (en) 2010-12-02 2017-07-05 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for ctla-4
AU2012350654C1 (en) * 2011-12-12 2018-05-10 Pieris Ag Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
ES2710384T3 (es) * 2011-12-13 2019-04-24 Pieris Pharmaceuticals Gmbh Procedimientos para la prevención o el tratamiento de determinados trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores
MY175188A (en) * 2012-01-09 2020-06-13 Pieris Ag Methods for preventing, treating or diagnosing disorders
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
WO2014076321A1 (en) 2012-11-19 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
HK1213194A1 (zh) 2013-03-14 2016-06-30 Daiichi Sankyo Co., Ltd. 用於新型的结合蛋白质pcsk9
EP3094650A2 (en) * 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
SG11201609274SA (en) * 2014-05-22 2016-12-29 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
JP6839087B2 (ja) 2015-01-28 2021-03-03 ピエリス ファーマシューティカルズ ゲーエムベーハー 血管新生に特異的な新規のタンパク質
TN2017000348A1 (en) 2015-02-18 2019-01-16 Sanofi Sa Novel proteins specific for pyoverdine and pyochelin
KR102734408B1 (ko) * 2015-05-04 2024-11-27 피어이스 파마슈티컬즈 게엠베하 Cd137에 특이적인 신규한 단백질
KR20170138574A (ko) * 2015-05-04 2017-12-15 피어이스 파마슈티컬즈 게엠베하 항암 융합 폴리펩타이드
AU2016262838B2 (en) 2015-05-18 2020-10-08 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
MX390894B (es) * 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
EP3115371A1 (en) * 2015-07-07 2017-01-11 Sanofi Fusion molecules
KR20180029238A (ko) * 2015-07-15 2018-03-20 피어이스 파마슈티컬즈 게엠베하 Lag-3에 특이적인 신규 단백질
TW201725212A (zh) * 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
WO2018134274A1 (en) * 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for lag-3
CA3100119A1 (en) * 2018-07-31 2020-02-06 Pieris Pharmaceuticals Gmbh Fusion protein specific for cd137 and pd-l1
CN112955221A (zh) * 2018-08-27 2021-06-11 皮里斯制药有限公司 包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途
MX2021010039A (es) * 2019-02-26 2021-09-21 Pieris Pharmaceuticals Gmbh Novedosas proteinas de fusion especificas para cd137 y gpc3.
US20220193191A1 (en) * 2019-03-29 2022-06-23 Astrazeneca Ab Lipocalin mutein for treatment of asthma
AU2021285201A1 (en) * 2020-06-05 2022-11-24 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1BB
US20230366884A1 (en) * 2020-09-18 2023-11-16 Pieris Pharmaceuticals Gmbh Biomarker methods and uses

Similar Documents

Publication Publication Date Title
US6616914B2 (en) Method for pulmonary and oral delivery of pharmaceuticals
ES2780127T3 (es) Formulación superfina de formoterol
JP2025037885A (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
AU2007298814B2 (en) Galenic form for the trans-mucosal delivery of active ingredients
CN102325532B (zh) 用于减轻肺部炎症的左氧氟沙星吸入剂
JP2023086774A (ja) 乾燥粉末配合および使用方法
JP2774379B2 (ja) 医薬エアロゾール組成物ならびにそれらのウイルス疾患の治療および予防用途
KR20100091970A (ko) 파킨슨병 치료용 조성물
WO2017027402A1 (en) Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (en) Methods for the treatment of mast cell related disorders with mast cell stabilizers
CA3030971A1 (en) Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
Kaur et al. Advanced aerosol delivery devices for potential cure of acute and chronic diseases
CN110505873B (zh) 鼻内肾上腺素制剂及治疗疾病的方法
EP4138832A1 (en) Products of manufacture and methods for treating, ameliorating or preventing microbial infections
Jin et al. RETRACTED: Pulmonary route of administration is instrumental in developing therapeutic interventions against respiratory diseases
Mukherjee et al. Pulmonary administration of biodegradable drug nanocarriers for more efficacious treatment of fungal infections in lungs: Insights based on recent findings
IT202000005026A1 (it) Lattoferrina per uso inalatorio ad azione antivirale
CN106667974A (zh) 一种吸入用硫酸特布他林溶液制备方法
JP2019516797A5 (https=)
JPWO2020201038A5 (https=)
JP2023551989A (ja) 生成物送達デバイス及び方法
CN118806738A (zh) 一种吸入施用的药物制剂及其在医药上的应用
Deka et al. Resperetory disease and need for efficient drug delivery system
WO2001015777A1 (en) Pulmonary-administration of mineral ascorbates
JP2003513048A (ja) 気道狭窄の治療のための酸化窒素の使用